Centessa Pharmaceuticals plc(CNTA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Centessa Pharmaceuticals plc (CNTA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CNTA at 14.9/100 on a 32-signal composite quality model, placing it at rank #2,858 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of CNTA by reported 13-F value include Medicxi Ventures Management (Jersey) Ltd, Avoro Capital Advisors, Index Venture Life Associates VI Ltd, based on the most recent SEC filings. CNTA trades on the Nasdaq exchange and files with the SEC under CIK 1847903. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Centessa Pharmaceuticals plc directly from SEC EDGAR.

AI Quality Score

14.9/100

AI Rank

#2,858

Revenue

$0.00

Net Income

$-79.2M

CNTA key financials by period

Centessa Pharmaceuticals plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$15.0M$-197.5M—
FY 202310-K$6.9M$-151.1M—

Institutions holding CNTA

Institutional investors reporting a position in Centessa Pharmaceuticals plc on SEC Form 13F.
InstitutionSharesValueReported
Medicxi Ventures Management (Jersey) Ltd19,963,157$792.9M2026-03-31
Avoro Capital Advisors11,430,455$454.0M2026-03-31
Index Venture Life Associates VI Ltd9,961,789$395.7M2026-03-31
ADAGE CAPITAL PARTNERS GP, L.L.C.8,925,010$354.5M2026-03-31
Pentwater Capital Management8,170,000$324.5M2026-03-31
FMR6,852,047$272.2M2026-03-31
EcoR1 Capital6,000,000$238.3M2026-03-31
PERCEPTIVE ADVISORS5,258,903$208.9M2026-03-31
Capital World Investors4,832,548$191.9M2026-03-31
FARALLON CAPITAL MANAGEMENT4,809,000$191.0M2026-03-31
SEC EDGAR: CIK 1847903 →
CNTA

Centessa Pharmaceuticals plc

CNTA
NasdaqMid CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

14.9/100

Rank #2,858 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q1 2026
EDGAR

$0

Net Income

Q1 2026
EDGAR

$-79.24M

EPS (Diluted)

Q1 2026
EDGAR

$-0.52

ROIC

Q1 2026
EDGAR

-53.4%

Debt/Equity

Q1 2026
EDGAR

0.23

Top Institutional Holders

as of Q1 2026
$5.95B total
Medicxi Ventures Management (Jersey) Ltd
$792.94M0.0%
Avoro Capital Advisors LLC
$454.02M-21.5%
Index Venture Life Associates VI Ltd
$395.68M0.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$354.50M-20.9%
Pentwater Capital Management LP
$324.51MNew
FMR LLC
$272.16M-23.5%
EcoR1 Capital, LLC
$238.32M+92.6%
PERCEPTIVE ADVISORS LLC
$208.88M+80.2%
Capital World Investors
$191.95M+317.1%
FARALLON CAPITAL MANAGEMENT LLC
$191.01M-10.6%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…